共 50 条
- [41] Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencingJOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6Ferrer-Marin, FranciscaBellosillo, BeatrizMartinez-Aviles, LuzSoler, GloriaCarbonell, PabloLuengo-Gil, GinesCaparros, EvaTorregrosa, Jose M.Besses, CarlosVicente, Vicente
- [42] Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in micePLOS ONE, 2020, 15 (02):Staehle, Hans F.Heinemann, JohannesGruender, AlbertOmlor, Anne M.Pahl, Heike LuiseJutzi, Jonas Samuel
- [43] IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FLEUKEMIA, 2012, 26 (03) : 475 - 480Tefferi, A.Jimma, T.Sulai, N. H.Lasho, T. L.Finke, C. M.Knudson, R. A.McClure, R. F.Pardanani, A.
- [44] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLINVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 340 - 349Jeon, Jae YoonZhao, QiuhongBuelow, Daelynn R.Phelps, MitchWalker, Alison R.Mims, Alice S.Vasu, SumithiraBehbehani, GregoryBlachly, JamesBlum, WilliamKlisovic, Rebecca B.Byrd, John C.Garzon, RamiroBaker, Sharyn D.Bhatnagar, Bhavana
- [45] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLInvestigational New Drugs, 2020, 38 : 340 - 349Jae Yoon JeonQiuhong ZhaoDaelynn R. BuelowMitch PhelpsAlison R. WalkerAlice S. MimsSumithira VasuGregory BehbehaniJames BlachlyWilliam BlumRebecca B. KlisovicJohn C. ByrdRamiro GarzonSharyn D. BakerBhavana Bhatnagar
- [46] JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2BLOOD, 2014, 124 (19) : 2996 - 3006Kagoya, YukiYoshimi, AkihideTsuruta-Kishino, TakakoArai, ShunyaSatoh, TakashiAkira, ShizuoKurokawa, Mineo
- [47] Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptorPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (47) : 18502 - 18507Pradhan, AnuradhaLambert, Que T.Reuther, Gary W.
- [48] Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56α subunitEXPERIMENTAL HEMATOLOGY, 2016, 44 (12) : 1156 - 1165Kawashima, IchiroKirito, Keita
- [49] Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapyONCOTARGETS AND THERAPY, 2014, 7 : 1043 - 1050Musto, PellegrinoSimeon, VittorioGuariglia, RobertoBianchino, GabriellaGrieco, VitinaNozza, FilomenaLa Rocca, FrancescoMarziano, GioacchinoLalinga, Anna VittoriaFabiani, EmilianoVoso, Maria TeresaScaravaglio, PatriziaMecucci, CristinaD'Arena, Giovanni
- [50] Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasmsLEUKEMIA RESEARCH, 2010, 34 (10) : 1390 - 1394Fung, Tsz-KanCheung, Alice M. S.Kwong, Yok-LamLiang, RaymondLeung, Anskar Y. H.